|
|
Other links at Articles > Allergy and Clinical Immunology |
| 3. |
FDA Safety Changes: Atrovent and Atripla
|
|
|
The FDA has approved revisions to the safety labeling for ipratropium Br nasal spray (Atrovent) and for efavirenz/emtricitabine/tenofovir disoproxil fumarate tablets (Atripla).
Medscape Medical News
|
|
|